-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130

Benzinga·08/05/2026 13:27:57
语音播报
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.